Millennium Pharmaceuticals, Inc. (MLNM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Ian@SI	6/15/2006 2:24:33 PM
	of 3044

Millennium Responds to Market Report 14:21 EDT Thursday, June 15, 2006 CAMBRIDGE, Mass., June 15 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) issued today the following statement in response to a market report: As a result of an offer to acquire Millennium initiated by a third party, the Company had engaged in a time-limited process to explore a strategic sale relative to the Company's stated strategy of building a sustainable biopharmaceutical company. The Company has ended this process and will continue to focus on its stated strategy by growing sales of its market-leading cancer product VELCADE(R) (bortezomib) for Injection, progressing a pipeline of seven novel product candidates and achieving profitable growth long-term. (Logo: newscom.com ) The Company generally does not respond to market rumors and does not expect to provide further comment.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next